Immunotherapy in Urothelial Bladder Cancer: Current Treatments and Emerging Research

The Immunotherapy in Urothelial Bladder Cancer: Current Treatments and Emerging Research, content and views expressed therein are those of the Clinical Care Options, LLC and not of SITC.


  • Welcome and Introduction  
  • Clinical Rationale for Immune Checkpoint Blockade in Urothelial Carcinoma
  • Current Clinical Experience With PD-1/PD-L1 Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
  • Ongoing Research and New Horizons for Immune-Based Bladder Cancer Treatment
  • Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer Session


Program Chair
Elizabeth R. Plimack, MD

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology

Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating immunotherapy into the treatment of patients with bladder cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with urothelial bladder cancer.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Evaluate the benefits of using immune checkpoint inhibitors as single agents or in combination with other therapies to treat patients with urothelial carcinoma
  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, patient and disease characteristics, as well as patient preferences
  • Discuss ongoing clinical trials investigating immune checkpoint inhibitors in the treatment of MIBC and NMIBC
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.